BIOAI COMPANY VALIDATION NEWS PHARMA LONGEVITY CONTACT PHARMA LOGIN

VALIDATION

Validated by Pharma. Backed by Science.

Pharmaceutical collaborations, award-winning innovation and peer-reviewed research.

Quris founder and CEO Isaac Bentwich holding the 2023 Scrip Award. — SCRIP AWARD WINNER · CLOSING THE CLINICAL PREDICTION GAP

pharmaceutical validation

Validated in Pharmaceutical Research

Quris has evaluated its BioAI platform through blinded studies with leading pharmaceutical companies. Its publicly announced collaboration with Merck KGaA has progressed from validation to integration into preclinical drug safety evaluation.

Merck KGaA, Darmstadt, Germany

Publicly announced collaboration

01Blinded Validation
Prospective evaluation of drug-safety prediction.
02Platform Integration
BioAI integrated into Merck's preclinical safety evaluation workflow.
03Multi-Year Collaboration
Expanded commercial scanning following validation.

Read the Merck KGaA Announcement

Additional Top-10 Pharma Collaborations

Beyond Merck KGaA, Quris collaborates with other leading global pharmaceutical companies, including top-10 pharma partners, on blinded evaluations, drug-safety studies and the development of new capabilities.

Partner identities remain confidential.

awards & recognition

Award-Winning Innovation

Awards won, and independent recognition of the platform and the science behind it.

Scrip Innovation AwardWinner · 2023

Closing the Clinical Prediction Gap

The 2023 Scrip Awards, the 19th edition of the global biopharma awards, recognised Quris-AI in its Innovation Award category for the entry “Quris-AI Closes the Clinical Prediction Gap.”

The Scrip announcement

Still from the 2023 Scrip Innovation Award announcement for Quris-AI

Watch the award moment

Frost & Sullivan2023

Global Technology Innovation Leadership Award

AI-based drug safety prediction.

Fast Company2023

World's Most Innovative Companies

Named to the 2023 annual list.

Global Excellence Awards — Best AI-Pharma Company, Israel

For the Bio-AI clinical prediction platform.

Frost & Sullivan2022

European Technology Innovation Leadership Award

Announced August 31, 2022.

Independent analyst recognition

List inclusion · not an award win

Clarivate

2023 · Analyst recognition

Seven AI/ML Companies to Watch in Drug Development

Quris-AI was included in Clarivate's selection of AI companies to watch in drug development.

Additional recognition

published research

Science Behind BioAI

Peer-reviewed research advancing human tissue models, biological sensing and AI-driven drug safety assessment.

Featured publication

Nature
Communications

2026 · Open access

doi.org/10.1038/s41467-026-76936-z

Six-compound cocktail for maturation of human pluripotent stem cell-derived liver spheroids for toxicity prediction

A defined six-compound cocktail improves maturation of stem cell-derived liver spheroids and their prediction of drug-induced liver injury.

August 21, 2026Read the paper

Frontiers in Bioengineering and Biotechnology2026

Non-invasive quantification of viability in liver spheroids using deep learning

Deep learning measures spheroid viability without disturbing the tissue.

Biomedicine & Pharmacotherapy2025

Multi-organ model assessment of neurotoxicity following exposure of liver spheroids to drugs

Links liver-metabolised compounds to neurotoxic effects across tissues.

Design and Synthesis of Novel Di-Boronic Acid-Based Chemical Glucose Sensors

New sensor chemistry for continuous biological glucose measurement.

Boronic Acid-Based Glucose Detection for Liver Three-Dimensional Cellular Models

Reads glucose metabolism inside 3D liver models and organ-on-chip systems.

Drug Discovery Today2023

Pharma's Bio-AI revolution

Perspective on AI, patient-on-chip, sensing and stem cells converging.

Perspective article, not an experimental study.

More milestones and coverage.

Explore Quris News & Press